Skip to main content
Caplight Logo









Noema Pharma

Noema Pharma

Private
BaselHealthcare & Life Scienceshttps://noemapharma.com/

Last Round

Series B

Extension

Dec 11, 2024

Total Funding Raised

$241M

Company Overview

Noema Pharma is a biotechnology company that develops innovative therapeutic solutions for central nervous system conditions, particularly targeting severe neurological disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalsmall molecule therapeuticsclinical-stage biotechneurological disorderspsychiatric disordersdrug discoveryclinical trialsmGluR5 inhibitorPDE10A inhibitortriple reuptake inhibitorrare disease drugorphan drugneuroscience therapeuticsbiotech pipelinedrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Noema Pharma Comparables

Compare Noema Pharma with similar companies based on industry and business-model similarity.

Noema Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Eumentis Therapeutics Inc.
83%
Addex Therapeutics
82%
Neurosterix
79%

Noema Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionDec 11, 2024
Series BMar 7, 2023
Series ADec 1, 2020

Key People

Founding team and executive leadership

Ilise Lombardo

Chief Executive Officer, Member Board Of Directors

Executive Team

Michael Samar

Chief Financial Officer

Executive Team

Noema Pharma Investors

Notable investors and investment history

Noema Pharma investors
InvestorRounds
BioMedPartnersSeries B, Series A
EQT Life SciencesSeries B Extension, Series B
ForbionSeries B
Gilde HealthcareSeries B, Series A, Series B Extension
Invus OpportunitiesSeries B, Series A, Series B Extension
Sofinnova PartnersSeries B, Series B Extension, Seed, Series A
UPMC EnterprisesSeries B, Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 8, 2025

    Michael Samar appointed as the new Chief Financial Officer.

  • Mar 7, 2023

    $147M round led by Jeito, EQT Life Sciences, and Forbion.

Noema Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Noema Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Noema Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersBasel
Employee Range34
Year Founded2019
Last FundingDec 11, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.